Compare Global X NASDAQ 100 Covered Call ETF (QYLD) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X NASDAQ 100 Covered Call ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? Global X NASDAQ 100 Covered Call ETF trades at $18.64 (market cap $8.54B), while Travere Therapeutics Inc. Common Stock trades at $53.44 (market cap $5.02B). The key difference: Global X NASDAQ 100 Covered Call ETF is the larger of the two by market cap, and Global X NASDAQ 100 Covered Call ETF is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X NASDAQ 100 Covered Call ETF for 51 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| QYLD | TVTX | |
|---|---|---|
Market Cap | $8.54B | $5.02B |
Volume | 2,727,578 | 2,060,842 |
Sector | Income / Options Overlay | Health |
52-Week High | $18.69 | $67.52 |
52-Week Low | $16.70 | $26.79 |
Typical Hold Time | 51 Days | 0 Days |
Enterprise Value | — | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QYLD trades at $18.69, showing minimal daily movement with a 0.05% gain. The ETF maintains its covered call strategy on the Nasdaq 100, generating consistent monthly dividends of $0.18 per share. Technical indicators show mixed signals with moving averages bullish but oscillators bearish, while RSI levels above 75 suggest overbought conditions. Recent news highlights concerns about principal erosion despite the attractive yield.
The outlook remains cautious as QYLD's high yield comes with capped upside potential during market rallies. While providing reliable monthly income, the strategy sacrifices long-term capital appreciation. Key risks include declining option premiums and tax treatment uncertainties that could impact total returns for income-focused investors.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
